Pharmacokinetic study of Tdp1 inhibitor resulted in a significant increase in antitumor effect in the treatment of Lewis lung carcinoma in mice by its combination with topotecan
- 18 September 2023
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 236, 115731
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education and Science of the Russian Federation (121031300041–4)
- Russian Science Foundation (21–14–00105)
This publication has 28 references indexed in Scilit:
- Tyrosyl-DNA Phosphodiesterase 1 Inhibitors: Usnic Acid Enamines Enhance the Cytotoxic Effect of CamptothecinJournal of Natural Products, 2016
- Biological activity of usnic acid and its derivatives: Part 2. effects on higher organisms. Molecular and physicochemical aspectsRussian Journal of Bioorganic Chemistry, 2016
- Biological activity of usnic acid and its derivatives: Part 1. Activity against unicellular organismsRussian Journal of Bioorganic Chemistry, 2016
- Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic targetDrug Metabolism Reviews, 2014
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial DrugsChemistry & Biology, 2010
- Amino-derivatives of usninic acidChemistry of Natural Compounds, 2009
- Tyrosyl-DNA Phosphodiesterase as a Target for Anticancer TherapyAnti-Cancer Agents in Medicinal Chemistry, 2008
- Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in miceJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell cultureCancer Letters, 1980